Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP)
暂无分享,去创建一个
J. Esteve | M. Labopin | J. Finke | D. Blaise | A. Nagler | D. Niederwieser | F. Frassoni | V. Rocha | T. Ruutu | A. Shimoni | S. Slavin | F Frassoni | T Ruutu | A Nagler | M Aoudjhane | M Labopin | N C Gorin | A Shimoni | H-J Kolb | J M Boiron | J L Yin | J Finke | H Shouten | D Blaise | M Falda | A A Fauser | J Esteve | E Polge | S Slavin | D Niederwieser | V Rocha | J. Boiron | A. Fauser | N. Gorin | M. Falda | J. Yin | H. Kolb | E. Polge | M. Aoudjhane | H. Shouten | On behalf of the inborn errors working party of Ebmt | on behalf of the Chronic Leukemia Working Party of th Ebmt
[1] A. Nagler,et al. Non-myeloablative stem cell transplantation (NST): chimerism testing as guidance for immune-therapeutic manipulations , 2001, Leukemia.
[2] J Crowley,et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.
[3] N. Kröger,et al. Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age>55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning , 2005, Leukemia.
[4] M. Maris,et al. Comparison of lung function after myeloablative and 2 Gy of total body irradiation-based regimens for hematopoietic stem cell transplantation. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[5] E. Estey,et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. , 1997, Blood.
[6] R. Storb,et al. Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning , 2005, Bone Marrow Transplantation.
[7] J. Sierra,et al. Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia , 2000, The Lancet.
[8] A. Nagler,et al. Non-myeloablative hematopoietic stem cell transplantation (NST) in the treatment of human malignancies: from animal models to clinical practice. , 2002, Cancer treatment and research.
[9] R. Storb,et al. Low-intensity allogeneic hematopoietic stem cell transplantation for myeloid malignancies: separating graft-versus-leukemia effects from graft-versus-host disease , 2005, Current opinion in hematology.
[10] C. Flowers,et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. , 2004, Blood.
[11] J P Klein,et al. Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. , 1999, Statistics in medicine.
[12] E. Estey,et al. Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years. , 2003, Blood.
[13] A. Nagler,et al. Nonmyeloablative stem cell transplantation: lessons from the first decade of clinical experience. , 2004, Current hematology reports.
[14] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[15] A. Rimm,et al. Graft-versus-leukemia reactions after bone marrow transplantation. , 1990, Blood.
[16] J. Gribben,et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. , 2004, Blood.
[17] C. Flowers,et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. , 2004, Blood.
[18] P. Hougaard,et al. Frailty models for survival data , 1995, Lifetime data analysis.
[19] S. Slavin,et al. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders. , 2003, Clinical transplants.
[20] D. Blaise,et al. The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison , 2005, Leukemia.
[21] J. Radich,et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] M. Maris,et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. , 2003, Blood.
[23] R. Champlin,et al. Allogeneic hematopoietic transplantation for acute and chronic myeloid leukemia: Non-myeloablative preparative regimens and induction of the graft-versus-leukemia effect , 2000, Current oncology reports.
[24] N. Ueno,et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. , 2000, British journal of haematology.
[25] J. Finke,et al. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] H. Einsele,et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. , 2005, Blood.
[27] J. Radich,et al. Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML , 2005, Leukemia.
[28] M. Labopin,et al. The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients with grade I acute graft-versus-host disease. Acute and Chronic Leukaemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). , 1996, Leukemia & lymphoma.
[29] R. Storb. Nonmyeloablative preparative regimens: how relevant for acute myelogenous leukemia? , 2001, Leukemia.
[30] K. Cleary,et al. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. , 2004, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[31] A A Rimm,et al. Outcome after allogeneic bone marrow transplant for leukemia in older adults. , 1993, JAMA.
[32] A. Nagler,et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. , 1998, Blood.
[33] S. Slavin. Reduced intensity versus truly nonmyeloablative conditioning for stem-cell transplant recipients. , 2004, Transplantation.
[34] J. Radich,et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. , 2001, Blood.
[35] M. Sorror,et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning , 2004 .
[36] M. Labopin,et al. Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia. A study of the European Cooperative Group for Blood and Marrow Transplantation (EBMT). , 1996, Bone marrow transplantation.